Does the CASR rs1801725 variant raise serum calcium and alter renal calcium handling?

The calcium-sensing receptor (CaSR) is a critical regulator of systemic divalent ion homeostasis. The CASR rs1801725 genetic variant represents a key modulator of this regulatory system, with distinct physiological consequences.

Mechanistic pathways of altered sensing

• Receptor desensitization: The rs1801725 variant (Ala986Ser) is a missense mutation located in the cytoplasmic tail of the CaSR. This variation acts as a mild inactivating mutation that reduces the receptor's sensitivity to extracellular calcium.
• Upward set-point shift: Because of this reduced sensitivity, a higher concentration of extracellular calcium is required to activate the receptor. This shifts the physiological set-point for calcium homeostasis upward, leading directly to elevated serum total and ionized calcium levels.

Clinical and renal evidence

• Serum calcium elevation: Large-scale genome-wide association studies show that the T (Ser) allele is robustly linked with modestly higher serum calcium, explaining over 1% of the overall population variance.
• Altered renal handling: Within the renal tubules, the shifted activation threshold alters tubular calcium reabsorption. While the impact on urinary calcium excretion is negligible in healthy cohorts, it becomes highly pronounced in predisposed populations.
• Kidney stone risk: In individuals with underlying conditions such as primary hyperparathyroidism or idiopathic hypercalciuria, this altered renal handling contributes to significantly elevated urinary calcium excretion (hypercalciuria), driving an increased risk of calcium-based kidney stone disease.

Bottom line

• The CASR rs1801725 (Ala986Ser) variant reduces receptor sensitivity to shift the homeostatic threshold upward, resulting in modestly higher serum calcium levels and altered renal calcium handling that increases hypercalciuria and kidney stone risk in susceptible individuals.